Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Tonyeight, Axeman, bnascomp, sunspotter, Shaz
Search This Board:
Last Post: 2/5/2016 4:46:52 PM - Followers: 188 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Amended Statement of Ownership (sc 13g/a) 02/05/2016 10:55:25 AM
#10774  Sticky Note The FDA approval news is now published on realbolod 01/20/16 09:57:18 AM
#10158  Sticky Note When people discuss likely biopharma penny stock scams sunspotter 01/04/16 10:38:19 AM
#8539  Sticky Note Rich Pharmaceuticals Receives FDA Approval for a Phase Shaz 12/28/15 08:12:17 AM
#10855   I meant what does the news mean? Hazmat927d 02/05/16 04:46:52 PM
#10854   It means Press Release realbolod 02/05/16 02:04:33 PM
#10853   Accidentally to you. That was supposed to be Hazmat927d 02/05/16 01:29:24 PM
#10852   What does the PR mean? Hazmat927d 02/05/16 01:28:19 PM
#10851   How many shares do u have? I am realbolod 02/05/16 11:56:30 AM
#10850   RCHA - Very well said! I'm certain Ben A1trader 02/05/16 08:57:52 AM
#10849   thermal...the way you casually said you heard about badshah 02/05/16 07:16:39 AM
#10848   The patent is the most valuable asset this thermal164 02/05/16 06:50:13 AM
#10847   in the local bar :) valleyview 02/05/16 04:46:08 AM
#10846   Where did you hear that? Hazmat927d 02/04/16 08:34:07 PM
#10845   I heard that now the litigation is settled thermal164 02/04/16 07:31:01 PM
#10844   Nothing. I'm waiting like everyone else. Hazmat927d 02/04/16 05:09:08 PM
#10843   you have any feedback from the company, or badshah 02/04/16 04:47:03 PM
#10842   Any day now Hazmat927d 02/04/16 04:28:46 PM
#10840   It might be heavy, but it's shiny tho... Leezee Life Strategies 02/03/16 03:18:01 PM
#10839   How those bags holding up? getting heavy? =) HMONNY 02/03/16 03:16:31 PM
#10838   "continued upward strength." sunspotter 02/02/16 05:55:39 AM
#10837   It should imply continued upward strength. AvowryLowry 02/02/16 03:45:10 AM
#10835   I agree, im in this but hate hearing bigsol33 02/01/16 04:21:30 PM
#10834   Last three posts....based on what....nothing. tiller 02/01/16 03:19:11 PM
#10833   News coming soon $$$ jpen3128 02/01/16 12:05:05 PM
#10832   News breaking out soon.. Richa heading for the realbolod 02/01/16 11:21:07 AM
#10831   RCHA BOUT TO CURE CANCER BABY !!! WEEEEEEEEEEEEEEEEEEEEEE! ! $$$RCHA Leezee Life Strategies 02/01/16 10:26:08 AM
#10830   We need a PR about an update. thermal164 02/01/16 10:01:58 AM
#10829   We need a PR about an update. thermal164 02/01/16 10:01:20 AM
#10828   Ben is the 8k's a shelter money onthegreen 01/29/16 05:10:06 PM
#10826   Im not blaming him. I blame myself, but The Pizzaman 01/29/16 03:26:52 PM
#10825   You might not want to call out his otclad 01/29/16 12:16:19 PM
#10824   The rest of the convertibles will only convert badshah 01/29/16 11:44:02 AM
#10823   Sad Tonyeight 01/29/16 09:45:10 AM
#10822   News won't help since there are another 5 Axeman 01/29/16 09:43:57 AM
#10821   Need bid Tonyeight 01/29/16 07:00:36 AM
#10820   News will be out soon!!!! thermal164 01/29/16 06:55:31 AM
#10819   LOL. No Bid More 8k's coming onthegreen 01/27/16 03:57:04 PM
#10818   LOL Hotstocked!! otclad 01/27/16 01:46:57 PM
#10817   I agree, thats the kind of news we bigsol33 01/27/16 08:32:08 AM
#10816   Nice effort but it will not help this Axeman 01/27/16 04:51:04 AM
#10815   RCHA EXPLOSIVE EARNINGS DATES AS REPORTED BY HOTSTOCKED.... stockaudit 01/27/16 01:09:02 AM
#10814   RCHA IMPORTANT EVENTS CALENDAR........ stockaudit 01/27/16 12:28:15 AM
#10813   What is average earning estimate? CashCassone 01/26/16 02:28:56 AM
#10811   I was actually just looking at the same M3dreamer 01/25/16 08:52:19 PM
#10810   Ben's dilution machine operates on news items. onthegreen 01/25/16 08:46:14 PM
#10808   From billions in volume 3 weeks ago, to Leezee Life Strategies 01/25/16 03:56:36 PM
#10807   You have answered your own question, RCHA is bearspread 01/25/16 11:42:12 AM
#10806   BE CAREFUL FOLLOWING PENNY STOCK TWITTER CLOWNS The Pizzaman 01/25/16 10:34:04 AM
#10805   7.5 Billion Diluted. More 8k's coming. Just like onthegreen 01/24/16 05:55:41 PM
#10803   Still a no bid scam Slydogg27 01/24/16 09:36:49 AM
#10802   RCHA - Thank you for highlighting their accomplishments, A1trader 01/24/16 09:20:13 AM
#10801   Litigation has been settled through a confidential mediation stockaudit 01/24/16 09:00:35 AM
#10800   Rich Pharmaceuticals Inc. published a letter of intent stockaudit 01/24/16 07:18:53 AM